
Opinion|Videos|May 1, 2024
The Role of Ruxolitinib in Managing Hydroxyurea Resistance or Intolerance
Gabriela Hobbs, MD, provides an overview of the role of ruxolitinib in treating patients with hydroxyurea-resistant or hydroxyurea-intolerant polycythemia vera.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Daraxonrasib trial exceeds expectations after decades of disappointment in pancreatic cancer drug development
2
340B reform and drug shortages are among hospital pharmacy concerns, survey finds
3
Dual-target ADC shows promising PFS signal in mCRPC | ASCO 2025
4
Alyana Samai, M.P.H. | 2026 MHE Emerging Leaders in Healthcare
5

























